Immuneering Presents Design of Ongoing Phase 3 MAPKeeper 301 Trial
Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeeper 301 trial evaluating atebimetinib with modified gemcitabine/nab.
Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeeper 301 trial evaluating atebimetinib with modified gemcitabine/nab.